What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?
-
ナレーター：
-
著者：
The Lymphoma Hub was pleased to speak with Christopher P. Fox, University of Nottingham, UK. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?
In this interview, Fox discusses the 3-year follow-up results from the global, randomized, phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) (n = 183) vs rituximab (R)-GemOx (n = 91) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), recently published in Blood Advances. He also explores outcomes across clinically relevant subgroups.
Intended for healthcare professionals. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.